These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30628547)

  • 1. Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir.
    Hamlin AN; Tillotson J; Bumpus NN
    Pharmacogenomics; 2019 Jan; 20(2):105-111. PubMed ID: 30628547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
    Fung HB; Stone EA; Piacenti FJ
    Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
    Pulido F; Fiorante S
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():13-8. PubMed ID: 19195433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].
    Bernardino de la Serna JI; Mora Rillo M; Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():7-12. PubMed ID: 19195432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysis.
    Ewald H; Santini-Oliveira M; Bühler JE; Vuichard D; Schandelmaier S; Stöckle M; Briel M; Bucher HC; Hemkens LG
    HIV Clin Trials; 2017 Jan; 18(1):17-27. PubMed ID: 27951755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir-based antiretroviral therapy in 
HBV-HIV coinfection: results from the TREAT Asia HIV Observational Database.
    Boettiger DC; Kerr S; Ditangco R; Chaiwarith R; Li PC; Merati TP; Pham TT; Kiertiburanakul S; Kumarasamy N; Vonthanak S; Lee CK; Van Kinh N; Pujari S; Wong WW; Kamarulzaman A; Zhang F; Yunihastuti E; Choi JY; Oka S; Ng OT; Kantipong P; Mustafa M; Ratanasuwan W; Durier N; Law M;
    Antivir Ther; 2016; 21(1):27-35. PubMed ID: 26069150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pulmonary hypertension in human immunodeficiency virus-infected patients: the role of antiretroviral therapy].
    Olalla J; Urdiales D; Pombo M; del Arco A; de la Torre J; Prada JL
    Med Clin (Barc); 2014 Mar; 142(6):248-52. PubMed ID: 23490486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.
    Nkhoma ET; Rosenblatt L; Myers J; Villasis-Keever A; Coumbis J
    PLoS One; 2016; 11(12):e0166982. PubMed ID: 27941989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substitution for protease inhibitors in HIV therapy.
    Mikhail E
    N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14689602
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects.
    Bongiovanni M; Fausto A; Cicconi P; Aliprandi A; Cornalba G; Bini T; Sardanelli F; D'Arminio Monforte A
    J Antimicrob Chemother; 2006 Aug; 58(2):485-6. PubMed ID: 16751202
    [No Abstract]   [Full Text] [Related]  

  • 15. Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI.
    Höring S; Löffler B; Pletz MW; Rößler S; Weis S; Schleenvoigt BT
    Infection; 2018 Oct; 46(5):599-605. PubMed ID: 29961209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
    Leeansyah E; Cameron PU; Solomon A; Tennakoon S; Velayudham P; Gouillou M; Spelman T; Hearps A; Fairley C; Smit de V; Pierce AB; Armishaw J; Crowe SM; Cooper DA; Koelsch KK; Liu JP; Chuah J; Lewin SR
    J Infect Dis; 2013 Apr; 207(7):1157-65. PubMed ID: 23303810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing issues related to antiretroviral therapy.
    Lesho EP; Gey DC
    Am Fam Physician; 2003 Aug; 68(4):675-86. PubMed ID: 12952384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
    Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
    HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Care of Patients With HIV Infection: Antiretroviral Drug Regimens.
    Bolduc P; Roder N; Colgate E; Cheeseman SH
    FP Essent; 2016 Apr; 443():23-30. PubMed ID: 27092564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.